2021年胰胆管细胞学实践:美国病理学家学会调查结果
美国病理学家学会(CAP)2021年非妇科细胞病理学教育项目附设胰胆管细胞学实践问卷,分析612家参与实验室数据。93%实验室常规评估胰胆管标本,胆道刷检(85%)最常见,其次为胰腺细针穿刺(79%)。调查首次揭示不同机构类型及国内外实验室在标本量、标本类型、快速现场评估(ROSE)与病例签发上存在显著差异。
要点
- 93%参与实验室常规开展胰胆管细胞学评估,胆道刷检与胰腺细针穿刺为主要标本类型
- 实性病变ROSE开展率达95%,囊性病变仅56%,囊性病变液基细胞学使用率59%
核心结论
- CAP首次胰胆管细胞学实践调查显示,不同机构类型及国内外实验室在标本量、标本类型、ROSE与病例签发方面存在显著差异。
- 这些数据为未来不同实践环境下的研究提供了基线。
研究设计与样本
- 分析CAP胰胆管细胞学实践补充问卷数据,问卷发放给参与2021年CAP非妇科细胞病理学教育项目的实验室。
- 612家应答实验室中567家(93%)常规评估胰胆管细胞学标本。
主要发现
- 胆道刷检(85%)是最常见的胰胆管细胞学标本,其次为胰腺细针穿刺(79%)。
- 235家实验室报告最常用取样方法为22G针细针穿刺(62%)与SharkCore针细针活检(27%)。
- 细胞块是最常用制片方法(76%),囊性病变液基细胞学使用率为59%。
- 320家实验室中95%(303家)对胰腺实性病变行ROSE,56%(180家)对囊性病变行ROSE。
关键数值与推荐
- 常规评估胰胆管细胞学标本的实验室比例为93%(567/612)。
- 胆道刷检使用率85%,胰腺细针穿刺使用率79%。
- 实性病变ROSE开展率95%(303/320),囊性病变ROSE开展率56%(180/320)。
临床怎么用
- 调查结果可作为病理科评估自身胰胆管细胞学实践配置的参照基线。
- ROSE在实性与囊性病变间开展率差异明显,可据此审视本机构资源配置。
- 报告系统使用率偏低,提示可关注标准化报告体系的推广。
局限性
- 原文未报告局限性相关内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT.—: The College of American Pathologists (CAP) surveys provide national benchmarks of pathology practice. OBJECTIVE.—: To investigate pancreaticobiliary cytology practice in domestic and international laboratories in 2021. DESIGN.—: We analyzed data from the CAP Pancreaticobiliary Cytology Practice Supplemental Questionnaire that was distributed to laboratories participating in the 2021 CAP Nongynecologic Cytopathology Education Program. RESULTS.—: Ninety-three percent (567 of 612) of respondent laboratories routinely evaluated pancreaticobiliary cytology specimens. Biliary brushing (85%) was the most common pancreaticobiliary cytology specimen evaluated, followed by pancreatic fine-needle aspiration (79%). The most used sampling methods reported by 235 laboratories were 22-gauge needle for fine-needle aspiration (62%) and SharkCore needle for fine-needle biopsy (27%). Cell block was the most used slide preparation method (76%), followed by liquid-based cytology (59%) for pancreatic cystic lesions. Up to 95% (303 of 320) of laboratories performed rapid on-site evaluation (ROSE) on pancreatic solid lesions, while 56% (180 of 320) performed ROSE for cystic lesions. Thirty-six percent (193 of 530) of laboratories used the Papanicolaou Society of Cytopathology System for Reporting Pancreaticobiliary Cytology in 2021. Among all institution types, significant differences in specimen volume, specimen type, ROSE practice, and case sign-out were identified. Additionally, significant differences in specimen type, slide preparation, and ROSE practice were found. CONCLUSIONS.—: This is the first survey from the CAP to investigate pancreaticobiliary cytology practice. The findings reveal significant differences among institution types and between domestic and international laboratories. These data provide a baseline for future studies in a variety of practice settings.
引用
- Li Z, Tabbara SO, Nwosu A, et al. Pancreaticobiliary Cytology Practice in 2021: Results of a College of American Pathologists Survey. Arch Pathol Lab Med. 2024. PMID: 37702405. doi:10.5858/arpa.2023-0167-CP
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。